COVID-19-Associated Liver Injury.

IF 2.6 Q2 GASTROENTEROLOGY & HEPATOLOGY

Hepatic Medicine : Evidence and Research Pub Date : 2023-01-01 DOI:10.2147/HMER.S384108

Daniel T Gildea, Stephanie M Woo, Corinne E O'Connor, Amol S Rangnekar

引用次数: 1

Abstract

This review analyzes data regarding liver injury associated with COVID-19 infection. We discuss reported effects on the liver from both COVID-19 and COVID-19 treatment as well as pathophysiology, review the potential role of drug-induced liver injury as an etiology of COVID-19-associated liver injury, and touch on other reports of significant outcomes including COVID-19 cholangiopathy and autoimmune hepatitis. Finally, we review the implications of COVID-19 infection in liver transplant recipients.

Abstract Image

查看原文本刊更多论文

covid -19相关肝损伤。

本综述分析了与COVID-19感染相关的肝损伤数据。我们讨论了已报道的COVID-19和COVID-19治疗对肝脏的影响以及病理生理学，回顾了药物性肝损伤作为COVID-19相关肝损伤病因的潜在作用，并讨论了其他重要结局的报道，包括COVID-19胆管病和自身免疫性肝炎。最后，我们回顾了COVID-19感染对肝移植受者的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Medicine : Evidence and Research GASTROENTEROLOGY & HEPATOLOGY-

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： Hepatic Medicine: Evidence and Research is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric hepatology in the clinic and laboratory including the following topics: Pathology, pathophysiology of hepatic disease Investigation and treatment of hepatic disease Pharmacology of drugs used for the treatment of hepatic disease Although the main focus of the journal is to publish research and clinical results in humans; preclinical, animal and in vitro studies will be published where they will shed light on disease processes and potential new therapies. Issues of patient safety and quality of care will also be considered. As of 1st April 2019, Hepatic Medicine: Evidence and Research will no longer consider meta-analyses for publication.